The Value of Ammonia as a Biomarker in Patients with Cirrhosis.

IF 4.3 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Seminars in liver disease Pub Date : 2024-08-01 Epub Date: 2024-08-02 DOI:10.1055/a-2378-8942
Maria Pilar Ballester, Esra Nur Durmazer, Tingting Qi, Rajiv Jalan
{"title":"The Value of Ammonia as a Biomarker in Patients with Cirrhosis.","authors":"Maria Pilar Ballester, Esra Nur Durmazer, Tingting Qi, Rajiv Jalan","doi":"10.1055/a-2378-8942","DOIUrl":null,"url":null,"abstract":"<p><p>Ammonia is a product of amino acid metabolism that accumulates in the blood of patients with cirrhosis and plays a pivotal role in the pathogenesis of hepatic encephalopathy (HE). Despite being one of the main drivers of brain dysfunction, for many years international societies stated that increased blood ammonia does not add any diagnostic, staging, or prognostic value for HE in patients with cirrhosis. Nonetheless, in the last decades, evidence is emerging that supports the utility of ammonia for risk stratification, but its role in guiding HE diagnosis, staging, and treatment is unclear and there is equipoise in its use in clinical practice. This review provides the latest evidence on the value of ammonia as a biomarker in patients with cirrhosis. Although correct measurement of ammonia requires disciplined sample collection, it provides extremely useful clinical guidance for the diagnosis of HE, offers prognostic information, and it defines a therapeutic target.</p>","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"356-368"},"PeriodicalIF":4.3000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449525/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in liver disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2378-8942","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Ammonia is a product of amino acid metabolism that accumulates in the blood of patients with cirrhosis and plays a pivotal role in the pathogenesis of hepatic encephalopathy (HE). Despite being one of the main drivers of brain dysfunction, for many years international societies stated that increased blood ammonia does not add any diagnostic, staging, or prognostic value for HE in patients with cirrhosis. Nonetheless, in the last decades, evidence is emerging that supports the utility of ammonia for risk stratification, but its role in guiding HE diagnosis, staging, and treatment is unclear and there is equipoise in its use in clinical practice. This review provides the latest evidence on the value of ammonia as a biomarker in patients with cirrhosis. Although correct measurement of ammonia requires disciplined sample collection, it provides extremely useful clinical guidance for the diagnosis of HE, offers prognostic information, and it defines a therapeutic target.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
氨作为肝硬化患者生物标志物的价值。
氨是氨基酸代谢的产物,会在肝硬化患者的血液中蓄积,在肝性脑病(HE)的发病机制中起着关键作用。尽管血氨是脑功能障碍的主要驱动因素之一,但多年来,国际学会一直认为血氨升高对肝硬化患者的肝性脑病并无任何诊断、分期或预后价值。然而,在过去的几十年中,越来越多的证据支持血氨用于风险分层,但其在肝硬化诊断、分期和治疗中的指导作用尚不明确,在临床实践中的应用也不尽相同。本综述提供了有关氨作为肝硬化患者生物标志物价值的最新证据。虽然氨的正确测量需要规范的样本采集,但它为肝硬化的诊断提供了非常有用的临床指导,提供了预后信息,并确定了治疗目标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Seminars in liver disease
Seminars in liver disease 医学-胃肠肝病学
CiteScore
8.20
自引率
2.40%
发文量
38
期刊介绍: Seminars in Liver Disease is a quarterly review journal that publishes issues related to the specialties of hepatology and gastroenterology. As the premiere review journal in the field, Seminars in Liver Disease provides in-depth coverage with articles and issues focusing on topics such as cirrhosis, transplantation, vascular and coagulation disorders, cytokines, hepatitis B & C, Nonalcoholic Steatosis Syndromes (NASH), pediatric liver diseases, hepatic stem cells, porphyrias as well as a myriad of other diseases related to the liver. Attention is also given to the latest developments in drug therapy along with treatment and current management techniques. Seminars in Liver Disease publishes commissioned reviews. Unsolicited reviews of an exceptional nature or original articles presenting remarkable results will be considered, but case reports will not be published.
期刊最新文献
Role of the Gut Microbiome in Metabolic Dysfunction-Associated Steatotic Liver Disease. HBV Biomarkers and Their Role in Guiding Treatment Decisions. Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease. Managing Multiorgan Failure in Acute on Chronic Liver Failure. Advancements in MELD score and its impact in Hepatology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1